The global burden of Parkinson's disease has significantly increased, making it the second most common neurodegenerative disorder after Alzheimer's. Survival rates vary by subtype, with the diffuse malignant group having a median survival of only eight years. Early diagnosis remains a critical challenge, as the initial signs of neurodegeneration can occur long before motor symptoms emerge, highlighting the importance of identifying the disease sooner for better treatment outcomes.
